New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
12:28 EDTNAVBNavidea confirms FDA approval of expanded use for Lymphoseek
Navidea Biopharmaceuticals announced that the FDA has approved the Supplemental New Drug Application for the expanded use of Lymphoseek Injection indicated for guiding sentinel lymph node biopsy in head and neck cancer patients with squamous cell carcinoma of the oral cavity. Lymphoseek becomes the first and only FDA-approved radiopharmaceutical application for sentinel lymph node detection and was first approved in March 2013 for lymphatic mapping in breast cancer and melanoma patients.
News For NAVB From The Last 14 Days
Check below for free stories on NAVB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 7, 2014
07:20 EDTNAVBNavidea price target raised to $5 from $3 at JMP Securities
JMP Securities increased its price target on Navidea after the company reported higher than expected Q2 Lymphoseek sales and operating income. The firm thinks the company has a number of significant growth drivers and keeps an Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use